RTOG1216
OPEN TO ACCRUAL
PhII/III Cisplatin vs. Docetaxel-Cetuximab vs. Cisplatin-Atezolizumab for High Risk H&N
UW23121
OPEN TO ACCRUAL
Pilot Study of INCB081776
UW25009
OPEN TO ACCRUAL
Identifying biomarkers of oral cancer response to neoadjuvant immunotherapy prior to surgery
UW25107
OPEN TO ACCRUAL
FORTIFI-HN01: Ph 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combo w/Pembro for PD-L1+ HNSCC